Actualités

Pfizer stock has delivered a roughly 28% decline over the past five years, yet recent gains and a mixed set of valuation checks mean the current price is not an obvious bargain or clear bubble. With fresh product news and shifting expectations around its portfolio, investors are weighing whether the recent rebound leaves enough room for attractive long term returns. The share price is down about 28% over five years. This points to a company that has yet to fully reward long term holders...

AbbVie's growth engine is firing on all cylinders, but on its latest earnings call, analysts focused on whether the company can defend its turf and execute on its next big pipeline bet.

Healthcare stocks were lower late Friday afternoon, with the NYSE Healthcare Index decreasing 0.4% a

Bristol Myers wins FDA accelerated approval for Zenbexus, the first CELMoD therapy, as data show it doubles MRD-negative complete response rates.

Guido Oelkers will inherit a deep cancer pipeline, declining vaccine sales and $19 billion to fund the transition.

Valneva (NASDAQ:VALN) reported lower first-half revenue and wider losses for 2026, while maintaining its full-year sales outlook and emphasizing its cash position, restructuring measures and expectations for regulatory progress on its Lyme disease vaccine candidate with Pfizer. CEO Thomas Lingelbac

AbbVie's growth engine is firing on all cylinders, but on its latest earnings call, analysts focused on whether the company can defend its turf and execute on its next big pipeline bet.

In early August 2026, Pfizer Inc. reported second-quarter results showing revenue of US$15,034 million and a net loss of US$248 million, alongside US$4.30 billion in non-cash intangible asset impairments and a modest increase in full-year 2026 revenue guidance to US$60.50–US$62.50 billion. A key offsetting highlight was the positive Phase 3 data for Pfizer’s autoimmune drug LITFULO in nonsegmental vitiligo, underlining the growing importance of its non-COVID portfolio and broader immunology...

Moby summary of Spero Therapeutics, Inc.'s Q2 2026 earnings call

Well-known pharmaceutical companies such as Merck and Pfizer typically manage this complex process in house. Medpace Holdings which targets oncology, metabolic, cardiology, central nervous system, and anti-infective therapies, raised its 2026 revenue guidance on July’s second-quarter conference call to a midpoint of $2.85 billion, corresponding to a year-over-year increase of 13%. Three months later, Medpace is in the pink: On the heels of second-quarter earnings, the stock is up 14%.

SPRO strengthens its balance sheet and extends cash runway into 2029 while advancing its new SP001 immunology pipeline following the landmark approval of the first oral carbapenem antibiotic.

Pfizer’s second quarter results reflected stability in its core business despite ongoing challenges in COVID-related product demand. The company’s performance was shaped by strong execution in its non-COVID portfolio, with management highlighting robust revenue contributions from acquired brands and recent launches. CEO Albert Bourla attributed operational progress to “continued strategic progress” and emphasized the value generated by recent acquisitions such as Seagen and Biohaven. Management

The drugmaker's operating numbers are near the top of its class, but its stock performance is lagging the pack. Is the market seeing a risk that the fundamentals are missing.

Management raised its full-year forecast, but the market seems to be asking for more than a higher target.

Bristol Myers growth portfolio now accounts for 56% of revenues, led by key drugs, including Opdivo Qvantig, Reblozyl and Breyanzi, helping offset generic erosion.

PFE's non-COVID products are gaining momentum, with launches, acquisitions and a pipeline aimed at driving growth from 2029 onward.

RAS mutations fuel nearly a third of all cancers, and one biotech has quietly built the deepest late-stage pipeline targeting them. Now the biggest names in pharma are circling, and the math on who can actually write the check gets complicated fast.

The S&P 500's dividend yield just hit a record low, leaving income investors scrambling for alternatives. Five long-established index members still pay 6% or more, and all carry Buy ratings from top Wall Street analysts.

Pfizer (NYSE:PFE) agreed to a US$44 million class action settlement related to its smoking cessation drug Chantix, addressing claims tied to product safety disclosures. The company reported positive topline Phase 3 results for LITFULO in adults and adolescents with nonsegmental vitiligo, highlighting progress in its immunology pipeline. Both developments arrive as investors track Pfizer's legal exposures alongside late stage trial data that could inform future portfolio and revenue...

This healthcare giant is on a serious run, but with the stock trading at a peak, investors must decide if the powerful business engine has more fuel or if the price has already burned it all.

Pfizer sent shareholders a fortune in cash, yet the stock fell far behind the market, forcing a hard question about what all that money truly bought.

This problem has a solution, and Pfizer is implementing it.

Pfizer agreed to a $44 million Chantix settlement. Here's who may qualify, how to file a claim and the deadline to submit.

Both of these stocks pay more than double the S&P 500 average of 1.1%.

Non-COVID products surge 5% as Pfizer raises guidance and targets $9.7B in savings.

Pfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX), two companies forever linked by their historic COVID-19 vaccine partnership, reported Q2 2026 earnings alongside major strategic announcements. While the European Commission authorized their updated XFG-adapted COVID-19 vaccine on July 29, the two partners are traveling down very different paths. One is leveraging massive scale and aggressive cost-cutting […]

Eli Lilly's growth is huge, but on its latest call, analysts tested whether the next chapter can possibly live up to the last one.

The stock's 6.4% yield is attractive, but it comes with risk.

The case for more upside rests on its obesity pill, and what changed is not the drug but who can now write it and who can now pay for it.

Pfizer's Q2 beat and raised 2026 revenue outlook signal progress, but declining COVID sales and patent losses challenge its growth path.